Redox-based therapeutics in neurodegenerative disease

British Journal of Pharmacology

Volumn 174, Issue 12, 2017, Pages 1750-1770

  McBean, G J ^a   Lopez M G ^b   Wallner, F K ^c  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b INSTITUTO TEÓFILO HERNANDO   (Spain)

^c UNIVERSITY OF SKÖVDE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLOROPHENYL) 4 [3 (DIMETHYLAMINO)PHENYL] 5 METHYL 1H PYRAZOLO[4,3 C]PYRIDINE 3,6(2H,5H) DIONE; ACETYLCYSTEINE; ALLYLMERCAPTO ACETYLCYSTEINE; AMINOGUANIDINE; APOCYNIN; BARDOXOLONE METHYL; CARNOSIC ACID; CHLORPROMAZINE; CURCUMIN; DIPHENYLIODONIUM SALT; DIROXIMEL FUMARATE; FINGOLIMOD; GKT 136901; GLUTATHIONE; MANGANESE SUPEROXIDE DISMUTASE; ML 171; OXIDOPAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; RESVERATROL; SALAZOSULFAPYRIDINE; SULFORAPHANE; THIOREDOXIN REDUCTASE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAS 2870; VAS 3947; VERDIPERSTAT; ZONISAMIDE; ENZYME INHIBITOR;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; GLIOMA; HUMAN; MEMORY DISORDER; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE; UBIQUITINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DEGENERATIVE DISEASE; DRUG EFFECTS; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION;

ANIMALS; ENZYME INHIBITORS; HUMANS; MITOCHONDRIA; NADPH OXIDASES; NEURODEGENERATIVE DISEASES; NITROSATIVE STRESS; OXIDATION-REDUCTION;

EID: 84992116486     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13551     Document Type: Review

References (211)

1. Aguirre J, Lambeth JD (2010). Nox enzymes from fungus to fly to fish and what they tell us about Nox function in mammals. Free Radic Biol Med 49: 1342–1353.
2. Akterin S, Cowburn RF, Miranda-Vizuete A, Jimenez A, Bogdanovic N, Winblad B et al. (2006). Involvement of glutaredoxin-1 and thioredoxin-1 in beta-amyloid toxicity and Alzheimer's disease. Cell Death Differ 13: 1454–1465.
3. Albano R, Liu X, Lobner D (2013). Regulation of system x(c)- in the SOD1-G93 A mouse model of ALS. Exp Neurol 250: 69–73.
4. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I et al. (2008a). Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 9: 686–696.
5. Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
6. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Overview. Br J Pharmacol 172: 5729–5143.
7. Alexander SPH, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E et al. (2015c). The Concise Guide to PHARMACOLOGY 2015/16: Transporters. Br J Pharmacol 172: 6110–6202.
8. Alexander SPH, Peters JA, Kelly E, Marrion N, Benson HE, Faccenda E et al. (2015d). The Concise Guide to PHARMACOLOGY 2015/16: Ligand-gated ion channels. Br J Pharmacol 172: 5870–5903.
9. Altenhöfer S, Radermacher KA, Kleikers PW, Wingler K, Schmidt HH (2014b). Evolution of NADPH oxidase inhibitors: selectivity and mechanisms for target engagement. Antioxid Redox Signal 23: 406–427.
10. Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P et al. (1994). Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30: 977–981.
11. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB (2007). Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807–818.
12. Aoyama T, Paik YH, Watanabe S, Laleu B, Gaggini F, Fioraso-Cartier L et al. (2012). Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatol 56: 2316–2327.
13. Apolloni S, Parisi C, Pesaresi MG, Rossi S, Carri MT, Cozzolino M et al. (2013). The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93 A microglia model of amyotrophic lateral sclerosis. J Immunol 190: 5187–5195.
14. Asanuma M, Miyazaki I, Diaz-Corrales FJ, Kimoto N, Kikkawa Y, Takeshima M et al. (2010). Neuroprotective effects of zonisamide target astrocyte. Ann Neurol 67: 239–249.
15. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA (2007). N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency. Curr Opin Pharmacol 7: 355–359.
16. Aytan N, Choi JK, Carreras I, Brinkmann V, Kowall NW, Jenkins BG et al. (2016). Fingolimod modulates multiple neuroinflammatory markers in a mouse model of Alzheimer's disease. Sci Rep 6: 24939.
17. Bal-Price A, Brown GC (2001). Inflammatory neurodegeneration mediated by nitric oxide from activated glia-inhibiting neuronal respiration, causing glutamate release and excitotoxicity. J Neurosci 21: 6480–6491.
18. Balogun E, Hoque M, Gong P, Killeen E, Green CJ, Foresti R et al. (2003). Curcumin activates the haem oxygenase-1 gene via regulation of Nrf2 and the antioxidant-responsive element. Biochem J 371: 887–895.
19. Bannai S (1984). Induction of cystine and glutamate transport activity in human fibroblasts by diethylmaleate and other electrophilic agents. J Biol Chem 259: 2435–2440.
20. Bentea E, Sconce MD, Churchill MJ, Van J, Sato H, Meshul CK et al. (2015a). MPTP-induced parkinsonism in mice alters striatal and nigral xCT expression but is unaffected by the genetic loss of xCT. Neurosci Lett 593: 1–6.
21. Bigford GE, Del Rossi G (2014). Supplemental substances derived from foods as adjunctive therapeutic agents for treatment of neurodegenerative diseases and disorders. Adv Nutr 5: 394–403.
22. Bomprezzi R (2015). Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview. Ther Adv Neurol Disord 8: 20–30.
23. Brandes R, Schroeder K, Page P, Laleu B, Gaggini F (2013). NADPH oxidase 4 inhibitors for prevention of osteoporosis or osteoglastogenesis dysfunction. PCT Int Appl Johann Wolfgang Goethe-Universitaet, Germany.
24. Bridges R, Lutgen V, Lobner D, Baker DA (2012). Thinking outside the cleft to understand synaptic activity: contribution of the cystine-glutamate antiporter (system xc−) to normal and pathological glutamatergic signaling. Pharmacol Rev 64: 780–802.
25. Brown GC, Cooper CE (1994). Nanomolar concentrations of nitric oxide inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 356: 295–298.
26. Cacciatore I, Baldassarre L, Fornasari E, Mollica A, Pinnen F (2012). Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems. Oxid Med Cell Longev 2012: 240146.
27. Carvalho AN, Lim JL, Nijland PG, Witte ME, Van J (2014). Glutathione in multiple sclerosis: more than just an antioxidant? Mult Scler 20: 1425–1431.
28. Casamenti F, Grossi C, Rigacci S, Pantano D, Luccarini I, Stefani M (2015). Oleuropein aglycone: a possible drug against degenerative conditions. In vivo evidence of its effectiveness against Alzheimer's disease. J Alzheimers Dis 45: 679–688.
29. Chandra V, Pandav R, Dodge HH, Johnston JM, Belle SH, DeKosky ST et al. (2001). Incidence of Alzheimer's disease in a rural community in India: the Indo-US study. Neurology 57: 985–989.
30. Chang J, Rimando A, Pallas M, Camins A, Porquet D, Reeves J et al. (2012). Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol Aging 33: 2062–2071.
31. Chen L, Li X, Liu L, Yu G, Xue Y, Liu Y (2015). Erastin sentizes glioblastoma cells to temozolomide by restraining xCT and cystathionine-g-lyase function. Oncol Rep 33: 1456–1474.
32. Chin MP, Reisman SA, Bakris GL, O'Grady M, Linde PG, McCullough PA et al. (2014). Mechanisms contributing to adverse cardiovascular events in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. Am J Nephrol 39: 499–508.
33. Cho HY (2013). Genomic structure and variation of nuclear factor (erythroid-derived 2)-like 2. Oxid Med Cell Longev 2013: 286524.
34. Choi DH, Cristovao AC, Guhathakurta S, Lee J, Joh TH, Beal MF et al. (2012). NADPH oxidase 1-mediated oxidative stress leads to dopamine neuron death in Parkinson's disease. Antioxid Redox Signal 16: 1033–1045.
35. Chung KK (2006). Say NO to neurodegeneration: role of S-nitrosylation in neurodegenerative disorders. Neurosignals 15: 307–313.
36. Cifuentes-Pagano E, Csanyi G, Pagano PJ (2012). NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS. Cell Mol Life Sci 69: 2315–2315.
37. Cobb CA, Cole MP (2015). Oxidative and nitrative stress in neurodegeneration. Neurobiol Dis 84: 4–21.
38. Colombo E, Di M, Capitolo E, Chaabane L, Newcombe J, Martino G et al. (2014). Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide. Ann Neurol 76: 325–337.
39. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, Diehl JA (2003). Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23: 7198–7209.
40. Daulatzai MA (2016). Fundamental role of pan-inflammation and oxidative-nitrosative pathways in neuropathogenesis of Alzheimer's disease. Am J Neurodegener Dis 5: 1–28.
41. Davinelli S, Sapere N, Zella D, Bracale R, Intrieri M, Scapagnini G (2012). Pleiotropic protective effects of phytochemicals in Alzheimer's disease. Oxid Med Cell Longev 2012: 386527.
42. De Groot JF, Sontheimer H (2011). Glutamate and the biology of the gliomas. Glia 59: 1181–1189.
43. Demetrius LA, Magistretti PJ, Pellerin L (2014). Alzheimer's disease: the amyloid hypothesis and the Inverse Warburg effect. Front Physiol 5: 522.
44. Dhakshinamoorthy S, Jaiswal AK (2001). Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene. Oncogene 20: 3906–3917.
45. Di F, Barone E, Perluigi M, Butterfield DA (2015). Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. Expert Rev Neurother 15: 19–40.
46. Díaz A, Rojas K, Espinosa B, Chavez R, Zenteno E, Limon D et al. (2014). Aminoguanidine treatment ameliorates inflammatory responses and memory impairment induced by amyloid-beta 25-35 injection in rats. Neuropeptides 48: 153–159.
47. Dinkova-Kostova AT, Talalay P (2008). Direct and indirect antioxidant properties of inducers of cytoprotective proteins. Mol Nutr Food Res 52 (Suppl 1): S128–S138.
48. Dong H, Xu L, Wu L, Wang X, Duan W, Li H et al. (2014). Curcumin abolished mutant TDP-43 induced excitability in a motoneuro-like cellular model of ALS. Neurosci 272: 141–153.
49. Dowding JM, Song W, Bossy K, Karakoti A, Kumar A, Kim A et al. (2014). Cerium oxide nanoparticles protect against Abeta-induced mitochondrial fragmentation and neuronal cell death. Cell Death Differ 21: 1622–1632.
50. Dranka BP, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy AG et al. (2013). Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R(1)(4)(4)(1)G) transgenic mouse. Neurosci Lett 549: 57–62.
51. Dranka BP, Gifford A, McAllister D, Zielonka J, Joseph J, O'Hara CL et al. (2014). A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease. Neurosci Lett 583: 159–164.
52. Dranka BP, Zielonka J, Kanthasamy AG, Kalyanaraman B (2012). Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation. J Neurochem 122: 941–951.
53. Dringen R, Pfeiffer B, Hamprecht B (1999). Synthesis of the antioxidant glutathione in neurons: supply by astrocytes of CysGly as precursor for neuronal glutathione. J Neurosci 19: 562–569.
54. Drummond GR, Sobey CG (2014). Endothelial NADPH oxidases: which NOX to target in vascular disease? Trends Endocrinol Metab 25: 452–463.
55. Dubey D, Cano CA, Stuve O (2016). Update on monitoring and adverse effects of approved second-generation disease-modifying therapies in relapsing forms of multiple sclerosis. Curr Opin Neurol 29: 278–285.
56. Dumont M, Wille E, Calingasan NY, Tampellini D, Williams C, Gouras GK et al. (2009). Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J Neurochem 109: 502–512.
57. Faulkner M (2015). Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis. Expert Opin Drug Saf 14: 1737–1748.
58. Fernando WM, Martins IJ, Goozee KG, Brennan CS, Jayasena V, Martins RN (2015). The role of dietary coconut for the prevention and treatment of Alzheimer's disease: potential mechanisms of action. Br J Nutr 114: 1–14.
59. Fiatarone Singh MA, Gates N, Saigal N, Wilson GC, Meiklejohn J, Brodaty H et al. (2014). The Study of Mental and Resistance Training (SMART) study-resistance training and/or cognitive training in mild cognitive impairment: a randomized, double-blind, double-sham controlled trial. J Am Med Dir Assoc 15: 873–880.
60. Fragoso YD, Sato HK (2016). Catastrophic magnetic resonance images in the central nervous system of patients undergoing treatment with Fingolimod. CNS Neurosci Ther.
61. Gaggini F, Laleu B, Orchard M, Fiorasi-Cartier L, Cagnon L, Houngninou-Molango S et al. (2011). Design, synthesis and biological activity of oridinal pyrazolo-pyrido-diazepine, −pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors. Bioorg Med Chem 19: 6989–6999.
62. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ (2007). Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. J Neurochem 102: 1095–1104.
63. Gatto GJ Jr, Ao Z, Kearse MG, Zhou M, Morales CR, Daniels E et al. (2013a). NADPH oxidase-dependent and -independent mechanisms of reported inhibitors of reactive oxygen generation. J Enzyme Inhib Med Chem 28: 95–104.
64. Gess B, Baets J, De Jonghe P, Reilly MM, Pareyson D, Young P (2015). Ascorbic acid for the treatment of Charcot–Marie-Tooth disease. Cochrane Database Syst Rev 12: Cd011952.
65. Gianni D, Taulet N, Zhang H, DerMardirossian C, Kister J, Martinez L et al. (2010). A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem Biol 5: 981–993.
66. Gout PW, Kang YJ, Buckley DJ, Bruchovsky N, Buckley AR (2001). Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the xc- cystine transporter: a new action for an old drug. Leukemia 15: 1633–1640.
67. Günther M, Davidsson J, Plantman S, Norgren S, Mathiesen T, Risling M (2015). Neuroprotective effects of N-acetylcysteine amide on experimental focal penetrating brain injury in rats. J Clin Neurosci 22: 1477–1483.
68. Haddad D, Nakamura K (2015). Understanding the susceptibility of dopamine neurons to mitochondrial stressors in Parkinson's disease. FEBS Lett 589: 3702–3713.
69. Hagl S, Kocher A, Schiborr C, Kolesova N, Frank J, Eckert GP (2015). Curcumin micelles improve mitochondrial function in neuronal PC12 cells and brains of NMRI mice - Impact on bioavailability. Neurochem Int 89: 234–242.
70. Harrison FE, Bowman GL, Polidori MC (2014). Ascorbic acid and the brain: rationale for the use against cognitive decline. Nutrients 6: 1752–1781.
71. Hayes JD, Dinkova-Kostova AT (2014). The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem Sci 39: 199–218.
72. Hensley K, Denton TT (2015). Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagement. Free Radic Biol Med 78: 123–134.
73. Hernandes MS, Cafe-Mendes CC, Britto LR (2013). NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice. Oxid Med Cell Longev 2013: 157857.
74. Heumuller S, Wind S, Barbosa-Sicard E, Schmidt HH, Busse R, Schroder K et al. (2008). Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 51: 211–217.
75. Hirano K, Chen WS, Chueng AL, Dunne AA, Seredenina T, Filippova A et al. (2015). Discovery of GSK2795039, a novel small molecule NADPH oxidase 2 inhibitor. Antioxid Redox Signal 23: 358–374.
76. Hirotani M, Maita C, Niino M, Iguchi-Ariga S, Hamada S, Ariga H et al. (2008). Correlation between DJ-1 levels in the cerebrospinal fluid and the progression of disabilities in multiple sclerosis patients. Mult Scler 14: 1056–1060.
77. Hourihan JM, Kenna JG, Hayes JD (2013). The gasotransmitter hydrogen sulfide induces nrf2-target genes by inactivating the keap1 ubiquitin ligase substrate adaptor through formation of a disulfide bond between cys-226 and cys-613. Antioxid Redox Signal 19: 465–481.
78. Hsieh TC, Lu X, Wang Z, Wu JM (2006). Induction of quinone reductase NQO1 by resveratrol in human K562 cells involves the antioxidant response element ARE and is accompanied by nuclear translocation of transcription factor Nrf2. Medicinal Chem 2: 275–285.
79. Hu X, Weng Z, Chu CT, Zhang L, Cao G, Gao Y et al. (2011). Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade. J Neurosci 31: 247–261.
80. Huang HC, Nguyen T, Pickett CB (2002). Phosphorylation of Nrf2 at Ser-40 by protein kinase C regulates antioxidant response element-mediated transcription. J Biol Chem 277: 42769–42774.
81. Infanger DW, Sharma RV, Davisson RL (2006). NADPH oxidases of the brain: distribution, regulation, and function. Antioxid Redox Signal 8: 1583–1596.
82. Innamorato NG, Rojo AI, Garcia-Yague AJ, Yamamoto M, de Caballos ML, Cuadrado A (2008). The transcription factor Nrf2 is a therapeutic target against brain inflammation. J Immunol 181: 680–689.
83. Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y et al. (2000). Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem 275: 16023–16029.
84. Jain AK, Jaiswal AK (2007). GSK-3beta acts upstream of Fyn kinase in regulation of nuclear export and degradation of NF-E2 related factor 2. J Biol Chem 282: 16502–16510.
85. Jazwa A, Rojo AI, Innamorato NG, Hesse M, Fernandez-Ruiz J, Cuadrado A (2011). Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental Parkinsonism. Antioxid Redox Signal 14: 2347–2360.
86. Jiang H, Tian X, Guo Y, Duan W, Bu H, Li C (2011). Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biol Pharm Bull 34: 1194–1197.
87. Jo C, Gundemir S, Pritchard S, Jin YN, Rahman I, Johnson GV (2014). Nrf2 reduces levels of phosphorylated tau protein by inducing autophagy adaptor protein NDP52. Nat Commun 5: 3496.
88. Johnson DA, Amirahmadi S, Ward C, Fabry Z, Johnson JA (2010). The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis. Toxicol Sci 114: 237–246.
89. Johnson WM, Wilson-Delfosse AL, Chen SG, Mieyal JJ (2015a). The roles of redox enzymes in Parkinson's disease: focus on glutaredoxin. Ther Targets Neurol Dis 2: e790.
90. Johnson WM, Wilson-Delfosse AL, Mieyal JJ (2012). Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 4: 1399–1440.
91. Johnson WM, Yao C, Siedlak SL, Wang W, Zhu X, Caldwell GA et al. (2015b). Glutaredoxin deficiency exacerbates neurodegeneration in C. elegans models of Parkinson's disease. Hum Mol Genet 24: 1322–1335.
92. Joseph JA, Fisher DR, Cheng V, Rimando AM, Shukitt-Hale B (2008). Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J Agric Food Chem 56: 10544–10551.
93. Jucaite A, Svenningsson P, Rinne JO, Cselenyi Z, Varnas K, Johnstrom P et al. (2015). Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. Brain 138: 2687–2700.
94. Juurlink BH, Thorburne SK, Hertz L (1998). Peroxide-scavenging deficit underlies oligodendrocyte susceptibility to oxidative stress. Glia 22: 371–378.
95. Kairane C, Mahlapuu R, Ehrlich K, Zilmer M, Soomets U (2014). The effects of different antioxidants on the activity of cerebrocortical MnSOD and Na,K-ATPase from post mortem Alzheimer's disease and age-matched normal brains. Curr Alzheimer Res 11: 79–85.
96. Kanakasabai S, Casalini E, Walline CC, Mo C, Chearwae W, Bright JJ (2012). Differential regulation of CD4(+) T helper cell responses by curcumin in experimental autoimmune encephalomyelitis. J Nutr Biochem 23: 1498–1507.
97. Kandil S, Brennan L, McBean GJ (2010). Glutathione depletion causes a JNK and p38MAPK-mediated increase in expression of cystathione-g-lyase and upregulation of the transulfuration pathway in C6 glioma cells. Neurochem Int 56: 611–619.
98. Kanninen K, Malm TM, Jyrkkanen HK, Goldsteins G, Keksa-Goldsteine V, Tanila H et al. (2008). Nuclear factor erythroid 2-related factor 2 protects against beta amyloid. Mol Cell Neurosci 39: 302–313.
99. Keum YS, Yu S, Chang PP, Yuan X, Kim JH, Xu C et al. (2006). Mechanism of action of sulforaphane: inhibition of p38 mitogen-activated protein kinase isoforms contributing to the induction of antioxidant response element-mediated heme oxygenase-1 in human hepatoma HepG2 cells. Cancer Res 66: 8804–8813.
100. Kim HV, Kim HY, Ehrlich HY, Choi SY, Kim DJ, Kim Y (2013). Amelioration of Alzheimer's disease by neuroprotective effect of sulforaphane in animal model. Amyloid 20: 7–12.
101. Kim JA, Neupane GP, Lee ES, Jeong BS, Park BC, Thapa P (2011). NADPH oxidase inhibitors: a patent review. Expert Opin Ther Pat 21: 1147–1158.
102. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T et al. (2004). Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 24: 7130–7139.
103. Kupershmidt L, Okun Z, Amit T, Mandel S, Saltsman I, Mahammed A et al. (2010). Metallocorroles as cytoprotective agents against oxidative and nitrative stress in cellular models of neurodegeneration. J Neurochem 113: 363–373.
104. La G, Weber P, Mohajeri MH (2014). Effects of vitamin E on cognitive performance during ageing and in Alzheimer's disease. Nutrients 6: 5453–5472.
105. Lafioniatis A, Orfanidou MA, Papadopoulou ES, Pitsikas N (2016). Effects of the inducible nitric oxide synthase inhibitor aminoguanidine in two different rat models of schizophrenia. Behav Brain Res 309: 14–21.
106. Laleu B, Gaggini F, Orchard M, Fiorasi-Cartier L, Cagnon L, Hougninou-Molango S et al. (2010). First in class, potent and orally bioavailable NADPH oxidase isoform 4 (NOX4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 53: 7715–7730.
107. Lancaster JR Jr (2006). Nitroxidative, nitrosative, and nitrative stress: kinetic predictions of reactive nitrogen species chemistry under biological conditions. Chem Res Toxicol 19: 1160–1174.
108. Lee C, Park GH, Lee SR, Jang JH (2013). Attenuation of beta-amyloid-induced oxidative cell death by sulforaphane via activation of NF-E2-related factor 2. Oxid Med Cell Longev 2013: 313510–313522.
109. Lee CT, Yu LE, Wang JY (2016). Nitroxide antioxidant as a potential strategy to attenuate the oxidative/nitrosative stress induced by hydrogen peroxide plus nitric oxide in cultured neurons. Nitric Oxide 54: 38–50.
110. Lewerenz J, Hewett S, Huang Y, Lambros M, Gout PW, Kalivas PW et al. (2013). The cystine/glutamate antiporter system xc- in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid Redox Signal 18: 522–555.
111. Li B, Cui W, Liu J, Li R, Liu Q, Xie XH et al. (2013). Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice. Exp Neurol 250: 239–249.
112. Li Y, Ganesh T, Diebold BA, Zhu Y, McCoy JW, Smith SM et al. (2015). Thioxo-dihydroquinazolin-one compounds as novel inhibitors of myeloperoxidase. ACS Med Chem Lett 6: 1047–1052.
113. Linker RA, Lee DH, Ryan S, Dam AM, Conrad R, Bista P et al. (2011a). Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 134: 678–692.
114. Lou H, Jing X, Wei X, Shi H, Ren D, Zhang X (2014). Naringenin protects against 6-OHDA-induced neurotoxicity via activation of the Nrf2/ARE signaling pathway. Neuropharmacology 79: 380–388.
115. Lu J, Wu L, Jiang T, Wang Y, Zhao H, Gao Q et al. (2015). Angiotensin AT2 receptor stimulation inhibits activation of NADPH oxidase and ameliorates oxidative stress in rotenone model of Parkinson's disease in CATH.a cells. Neurotoxicol Teratol 47: 16–24.
116. Ma Q, Battelli L, Hubbs AF (2006). Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am J Pathol 168: 1960–1974.
117. Ma T, Tan MS, Yu JT, Tan L (2014). Resveratrol as a therapeutic agent for Alzheimer's disease. Biomed Res Int 2014: 350516–350529.
118. Marrali G, Casale F, Salamone P, Fuda G, Caorsi C, Amoroso A et al. (2014). NADPH oxidase (NOX2) activity is a modifier of survival in ALS. J Neurol 261: 2178–2183.
119. Martin-de-Saavedra MD, Budni J, Cunha MP, Gomez-Rangel V, Lorrio S, Del L et al. (2013b). Nrf2 participates in depressive disorders through an anti-inflammatory mechanism. Psychoneuroendocrinology 38: 2010–2022.
120. Massie A, Schallier A, Sim SW, Fernando R, Kobayashi S, Beck H et al. (2011). Dopaminergic neurons of system xc- -deficient mice are highly protected against 6-hydroxydopamine-induced neurotoxicity. FASEB J 25: 1359–1369.
121. McBean GJ (2012). The transslfuration pathway: a source of cysteine for glutathione in astrocytes. Amino Acids 42: 199–205.
122. McBean GJ, Aslan M, Griffiths HR, Torrão R (2015). Thiol redox homeostasis in neurodegenerative disease. Redox Biol 5: 186–194.
123. McManus MJ, Murphy MP, Franklin JL (2011). The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 31: 15703–15715.
124. Meng P, Yoshida H, Matsumiya T, Imaizumi T, Tanji K, Xing F et al. (2013). Carnosic acid suppresses the production of amyloid-beta 1-42 by inducing the metalloprotease gene TACE/ADAM17 in SH-SY5Y human neuroblastoma cells. Neurosci Res 75: 94–102.
125. Menon VP, Sudheer AR (2007). Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105–125.
126. Mesci P, Zaïdi S, Lobsiger C, Millecamps S, Escartin C, Seilhean D et al. (2015). System xc- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice. Brain 138: 53–68.
127. Miyazaki I, Murakami S, Torigoe N, Kitamura Y, Asanuma M (2016). Neuroprotective effects of levetiracetam target xCT in astrocytes in parkinsonian mice. J Neurochem 136: 194–204.
128. Mohajeri M, Sadeghizadeh M, Najafi F, Javan M (2015). Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple slerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair. Neuropharmacol 99: 156–167.
129. Narasimhan M, Patel D, Vedpathak D, Rathinam M, Henderson G, Mahimainathan L (2012). Identification of nocel microRNAs in post-transcriptional control of Nrf2 expression and redox homeostasis in neuronal SH-SY5Y eclls. PLoS One 7: e51111.
130. Nayernia Z, Jaquet V, Krause KH (2014). New insights on NOX enzymes in the central nervous system. Antioxid Redox Signal 20: 2815–2837.
131. Ng TP, Chiam PC, Lee T, Chua HC, Lim L, Kua EH (2006). Curry consumption and cognitive function in the elderly. Am J Epidemiol 164: 898–906.
132. Okun Z, Gross Z (2012). Fine tuning the reactivity of corrole-based catalytic antioxidants. Inorg Chem 51: 8083–8090.
133. Ono K, Hasegawa K, Naiki H, Yamada M (2004). Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 75: 742–750.
134. Onyango IG, Dennis J, Khan SM (2016). Mitochondrial dysfunction in Alzheimer's disease and the rationale for bioenergetics based therapies. Aging Dis 7: 201–214.
135. Orlando RA, Gonzales AM, Royer RE, Deck LM, Vander Jagt DL (2012). A chemical analog of curcumin as an improved inhibitor of amyloid Abeta oligomerization. PLoS One 7: e31869.
136. Ozarowski M, Mikolajczak PL, Bogacz A, Gryszczynska A, Kujawska M, Jodynis-Liebert J et al. (2013). Rosmarinus officinalis L. leaf extract improves memory impairment and affects acetylcholinesterase and butyrylcholinesterase activities in rat brain. Fitoterapia 91: 261–271.
137. Pagano PJ, Wipf P, Cifuentes-Pagano ME, Skoda EM (2014). Preparation of bridged tetrahydroisoquinolines as selective NADPH oxidase 2 inhibitors. PCT Int Appl.
138. Page P, Gaggini F, Laleu B (2010). Pyrazoline dione derivatives as NADPH oxidase inhibitors. US Patent Office.
139. Page P, Laleu B, Gaggini F, Orchard M (2011). Preparation of pyrazolo piperidine derivatives as NADPH oxidase inhibitors. Eur Pat Appl GenKyoTex SA, Switzerland.
140. Pampliega O, Domercq M, Soria FN, Villoslada P, Rodríguez-Antigüedad A, Matute C (2011). Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflamm 8: 63–75.
141. Papa S, De D (2013). Complex I deficiencies in neurological disorders. Trends Mol Med 19: 61–69.
142. Park JA, Kim S, Lee SY, Kim CS, Kim K, Kim SJ et al. (2008b). Beneficial effects of carnosic acid on dieldrin-induced dopaminergic neuronal cell death. Neuroreport 19: 1301–1304.
143. Pehar M, Vargas MR, Cassina P, Barbeito AG, Beckman JS, Barbeito L (2005). Complexity of astrocyte-motor neuron interactions in amyotrophic lateral sclerosis. Neurodegener Dis 2: 139–146.
144. Perry TL, Yong VW (1986). Idiopathic Parkinson's disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67: 269–274.
145. Piani D, Fontana A (1994). Involvement of the cystine transport system xc- in the macrophage-induced glutamate-dependent cytotoxicity to neurons. J Immunol 152: 3578–3585.
146. Probst BL, Trevino I, McCauley L, Bumeister R, Dulubova I, Wigley WC et al. (2015). RTA 408, a novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS One 10: e0122942.
147. Pulido-Moran M, Moreno-Fernandez J, Ramirez-Tortosa C, Ramirez-Tortosa M (2016). Curcumin and Health. Molecules 21: E264.
148. Qin S, Colin C, Hinners I, Gervais A, Cheret C, Mallat M (2006). System xc- and apolipoprotein E expressed by microglia have opposite effects on the neurotoxicity of amyloid-beta peptide 1-40. J Neurosci 26: 3345–3356.
149. Radi R (2013). Protein tyrosine nitration: biochemical mechanisms and structural basis of functional effects. Acc Chem Res 46: 550–559.
150. Ramsey CP, Glass CA, Montgomery MB, Lindl KA, Ritson GP, Chia LA et al. (2007). Expression of Nrf2 in neurodegenerative diseases. J Neuropathol Exp Neurol 66: 75–85.
151. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ (2001). Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O2- and systolic blood pressure in mice. Circ Res 89: 408–414.
152. Rocha Lindner G, Bonfanti Santos D, Colle D, Gasnhar Moreira EL, Daniel Prediger R, Farina M et al. (2015b). Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine (Lond) 10: 1127–1138.
153. Rojo AI, McBean GJ, Cindric M, Egea J, López MG, Rada P et al. (2014). Redox control of microglial function: molecular mechanisms and functional significance. Antioxid Redox Signal 21: 1766–1801.
154. Rojo AI, Sagarra MR, Cuadrado A (2008). GSK-3beta down-regulates the transcription factor Nrf2 after oxidant damage: relevance to exposure of neuronal cells to oxidative stress. J Neurochem 105: 192–202.
155. Rushmore TH, King RG, Paulson KE, Pickett CB (1990). Regulation of glutathione S-transferase Ya subunit gene expression: identification of a unique xenobiotic-responsive element controlling inducible expression by planar aromatic compounds. Proc Natl Acad Sci U S A 87: 3826–3830.
156. Ruszkiewicz J, Albrecht J (2015). Changes in the mitochondrial antioxidant systems in neurodegenerative diseases and acute brain disorders. Neurochem Int 88: 66–72.
157. Sarlette A, Krampfl K, Grothe C, Neuhoff N, Dengler R, Petri S (2008). Nuclear erythroid 2-related factor 2-antioxidative response element signaling pathway in motor cortex and spinal cord in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 67: 1055–1062.
158. Sato H, Tamba M, Ishii T, Bannai S (1999). Cloning and expression of a plasma membane cystine/glutamate exchange transporter composed of two distinct proteins. J Biol Chem 274: 11455–11458.
159. Satoh T, Kosaka K, Itoh K, Kobayashi A, Yamamoto M, Shimojo Y et al. (2008). Carnosic acid, a catechol-type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1. J Neurochem 104: 1116–1131.
160. Savaskan E, Olivieri G, Meier F, Seifritz E, Wirz-Justice A, Muller-Spahn F (2003). Red wine ingredient resveratrol protects from beta-amyloid neurotoxicity. Gerontol 49: 380–383.
161. Savion N, Izigov N, Morein M, Pri-Chen S, Kotev-Emeth S (2014). S-Allylmercapto-N-acetylcysteine (ASSNAC) protects cultured nerve cells from oxidative stress and attenuates experimental autoimmune encephalomyelitis. Neurosci Lett 583: 108–113.
162. Schallier A, Smolders I, Van D, Loyens E, De PP, Michotte A et al. (2011b). Region- and age-specific changes in glutamate transport in the AbetaPP23 mouse model for Alzheimer's disease. J Alzheimers Dis 24: 287–300.
163. Schildknecht S, Weber A, Gerding HR, Pape R, Robotta M, Drescher M et al. (2014). The NOX1/4 inhibitor GKT136901 as selective and direct scavenger of peroxynitrite. Curr Med Chem 21: 365–376.
164. Schilling S, Goelz S, Linker R, Luehder F, Gold R (2006). Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145: 101–107.
165. Schmitt B, Vicenzi M, Garrel C, Denis FM (2015). Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers: a comparative crossover study. Redox Biol 6: 198–205.
166. Seidel P, Roth M (2013). Anti-inflammatory dimethylfumarate: a potential new therapy for asthma? Mediators Inflamm 2013: 875403–875413.
167. Seredenina T, Chiriano G, Filippova A, Nayernia Z, Mahiout Z, Fioraso-Cartier L et al. (2015). A subset of N-substituted phenothiazines inhibits NADPH oxidases. Free Radic Biol Med 86: 239–249.
168. Shimojo Y, Kosaka K, Noda Y, Shimizu T, Shirasawa T (2010). Effect of rosmarinic acid in motor dysfunction and life span in a mouse model of familial amyotrophic lateral sclerosis. J Neurosci Res 88: 896–904.
169. Silva-Adaya D, Gonsebatt ME, Guevara J (2014). Thioredoxin system regulation in the central nervous system: experimental models and clinical evidence. Oxid Med Cell Longev 2014: 590808–590825.
170. Slosky LM, Vanderah TW (2015). Therapeutic potential of peroxynitrite decomposition catalysts: a patent review. Expert Opin Ther Pat 25: 443–466.
171. Smeyne M, Smeyne RJ (2013). Glutathione metabolism and Parkinson's disease. Free Radic Biol Med 62: 13–25.
172. Solesio ME, Prime TA, Logan A, Murphy MP, Del M, Jordan J et al. (2013c). The mitochondria-targeted anti-oxidant MitoQ reduces aspects of mitochondrial fission in the 6-OHDA cell model of Parkinson's disease. Biochim Biophys Acta 1832: 174–182.
173. Sontheimer H, Bridges RJ (2012). Sulfasalazine for brain cancer fits. Expert Opin Investig Drugs 21: 575–578.
174. Sorce S, Krause KH (2009). NOX enzymes in the central nervous system: from signaling to disease. Antioxid Redox Signal 11: 2481–2504.
175. Sorce S, Krause KH, Jaquet V (2012). Targeting NOX enzymes in the central nervous system: therapeutic opportunities. Cell Mol Life Sci 69: 2387–2407.
176. Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SPH et al. (2016). The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucl Acids Res 44 (Database Issue): D1054–D1068.
177. Spencer CM, Crabtree-Hartman EC, Lehmann-Horn K, Cree BA, Zamvil SS (2015). Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2: e76.
178. Stolk J, Hiltermann TJ, Dijkman JH, Verhoeven AJ (1994). Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. Am J Respir Cell Mol Biol 11: 95–102.
179. Su ZY, Shu L, Khor TO, Lee JH, Fuentes F, Kong AN (2013). A perspective on dietary phytochemicals and cancer chemoprevention: oxidative stress, Nrf2 and epigenomics. Top Curr Chem 329: 133–162.
180. Sun QA, Hess DT, Wang B, Miyagi M, Stamler JS (2012). Off-target thiol alkylation by the NADPH oxidase inhibitor 3-benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo[4,5-d]pyrimidine (VAS2870). Free Radic Biol Med 52: 1897–1902.
181. Sun Z, Chin YE, Zhang DD (2009). Acetylation of Nrf2 by p300/CBP augments promoter-specific DNA binding of Nrf2 during the antioxidant response. Mol Cell Biol 29: 2658–2672.
182. Sunitha K, Hemshekhar M, Thushara RM, Santhosh MS, Yariswamy M, Kemparaju K et al. (2013). N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine. Free Radic Res 47: 357–367.
183. Tanji KA, Maruyame S, Odagiri F, Mori K, Itoh A, Kakita H et al. (2013). Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. J Neuropathol Exp Neurol 72: 18–28.
184. Tegtmeier F, Walter U, Schinzel R, Wingler K, Scheurer P, Schmidt H (2005). Compounds containing a N-heteroaryl moeity linked to fused ring moeities for the inhibition of NAD(P)H oxidases and platelet activation. European Patent Application EP1598354.
185. ten H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M et al. (2006). Novel NOX inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71: 331–341.
186. Thimmulappa RK, Mai KH, Srisuma S, Kensler TW, Yamamoto M, Biswal S (2002). Identification of Nrf2-regulated genes induced by the chemopreventive agent sulforaphane by oligonucleotide microarray. Cancer Res 62: 5196–5203.
187. Trials.gov C (2015). Safety and Efficacy of oral GKT137831 in patient with type 2 diabetes and albuminuria. Available from https://clinicaltrialsgov/ct2/show/study/NCT02010242.
188. Trumbull KA, McAllister D, Gandelman MM, Fung WY, Lew T, Brennan L et al. (2012). Diapocynin and apocynin administration fails to significantly extend survival in G93 A SOD1 ALS mice. Neurobiol Dis 45: 137–144.
189. Tsai YM, Chien CF, Lin LC, Tsai TH (2011). Curcumin and its nano-formulation: the kinetics of tissue distribution and blood–brain barrier penetration. Int J Pharm 416: 331–338.
190. Tsianakas A, Herzog S, Landmann A, Patsinakidis N, Perusquia Ortiz AM, Bonsmann G et al. (2014). Successful treatment of discoid lupus erythematosus with fumaric acid esters. J Am Acad Dermatol 71: e15–e17.
191. Uruno A, Furusawa Y, Yagishita Y, Fukutomi T, Muramatsu H, Negishi T et al. (2013). The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol Cell Biol 33: 2996–3010.
192. van Horssen J, Schreibelt G, Drexhage J, Hazes T, Dijkstra CD, van der Valk P et al. (2008). Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic Biol Med 45: 1729-1737.
193. van Horssen J, Drexhage JA, Flor T, Gerritsen W, Valk P, Vries HE (2010). Nrf2 and DJ1 are consistently upregulated in inflammatory multiple sclerosis lesions. Free Radic Biol Med 49: 1283–1289.
194. Vilhardt F, Haslund-Vinding J, Jaquet V, McBean G (2017). Microglia antioxidant systems and redox signalling. Brit J Pharmacol 174: 1719–1732.
195. Vitvitsky V, Thomas M, Ghorpade A, Gendelman HE, Banerjee RA (2006). A functional transsulfuration pathway in the brain links to GSH homeostasis. J Biol Chem 281: 25785–35793.
196. Wang YY, Yang YX, Zhe H, He ZX, Zhou SF (2014). Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Des Devel Ther 8: 2075–2088.
197. Wilkaniec A, Strosznajder JB, Adamczyk A (2013). Toxicity of extracellular secreted alpha-synuclein: its role in nitrosative stress and neurodegeneration. Neurochem Int 62: 776–783.
198. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME et al. (2010). Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161: 885–898.
199. Wu CR, Tsai CW, Chang SW, Lin CY, Huang LC, Tsai CW (2015). Carnosic acid protects against 6-hydroxydopamine-induced neurotoxicity in in vivo and in vitro model of Parkinson's disease: involvement of antioxidative enzymes induction. Chem Biol Interact 225: 40–46.
200. Wu KC, Cui JY, Klaassen CD (2011). Beneficial role of Nrf2 in regulating NADPH generation and consumption. Toxicol Sci 123: 590–600.
201. Xie L, Li XK, Funeshima-Fuji N, Kimura H, Matsumoto Y, Isaka Y et al. (2009). Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. Int Immunopharmacol 9: 575–581.
202. Xu Z, Zhang F, Sun F, Gu K, Dong S, He D (2015). Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev 4: Cd011076.
203. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS et al. (2005). Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 280: 5892–5901.
204. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC et al. (2009). Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 30: 1024–1031.
205. Yoshida H, Meng P, Matsumiya T, Tanji K, Hayakari R, Xing F et al. (2014). Carnosic acid suppresses the production of amyloid-beta 1-42 and 1-43 by inducing an alpha-secretase TACE/ADAM17 in U373MG human astrocytoma cells. Neurosci Res 79: 83–93.
206. Zaitone SA, Abo-Elmatty DM, Shaalan AA (2012). Acetyl-L-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy. Pharmacol Biochem Behav 100: 347–360.
207. Zawada WM, Mrak RE, Biedermann J, Palmer QD, Gentleman SM, Aboud O et al. (2015). Loss of angiotensin II receptor expression in dopamine neurons in Parkinson's disease correlates with pathological progression and is accompanied by increases in Nox4- and 8-OH guanosine-related nucleic acid oxidation and caspase-3 activation. Acta Neuropathol Commun 3: 9–25.
208. Zeevalk GD, Bernard LP, Guilford FT (2010). Liposomal-glutathione provides maintenance of intracellular glutathione and neuroprotection in mesencephalic neuronal cells. Neurochem Res 35: 1575–1587.
209. Zeevalk GD, Manzino L, Sonsalla PK, Bernard LP (2007). Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp Neurol 203: 512–520.
210. Zhang R, Miao QW, Zhu CX, Zhao Y, Liu L, Yang J et al. (2014). Sulforaphane ameliorates neurobehavioral deficits and protects the brain from amyloid beta deposits and peroxidation in mice with Alzheimer-like lesions. Am J Alzheimers Dis Other Demen 30: 183–191.
211. Zielonka J, Zielonka M, VerPlank L, Cheng G, Hardy M, Ouari O et al. (2016). Mitigation of NADPH oxidase 2 activity as a strategy to inhibit peroxynitrite formation. J Biol Chem 291: 7029–7044.